Skip to main content

Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production (2020)
Journal Article
Atkinson, S. K., Morice, A. H., & Sadofsky, L. R. (2020). Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production. ERJ Open Research, 6(4), https://doi.org/10.1183/23120541.00159-2020

Human rhinovirus (RV) is the most common cause of upper respiratory tract infection (URTI) and chronic airway disease exacerbation. Cough is present in 50–80% of URTI cases, accompanied by heightened airway hypersensitivity, yet no effective treatmen... Read More about Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production.

Azithromycin for sarcoidosis cough: an open label exploratory clinical trial (2020)
Journal Article
Fraser, S. D., Thackray-Nocera, S., Shepherd, M., Flockton, R., Wright, C., Sheedy, W., …Hart, S. P. (in press). Azithromycin for sarcoidosis cough: an open label exploratory clinical trial. ERJ Open Research, https://doi.org/10.1183/23120541.00534-2020

Background Chronic cough is a distressing symptom for many people with pulmonary sarcoidosis. Continuous treatment with a macrolide antibiotic may improve cough. We aimed to assess the potential efficacy of azithromycin in patients with sarcoidosis a... Read More about Azithromycin for sarcoidosis cough: an open label exploratory clinical trial.

Gefapixant A P2X3 Receptor Antagonist For The Treatment Of Refractory Or Unexplained Chronic Cough In A Phase 2b Randomised Controlled Trial (2020)
Journal Article
Smith, J. A., Kitt, M. M., Morice, A. H., Birring, S. S., McGarvey, L. P., Sher, M. R., …Ford, A. P. (in press). Gefapixant A P2X3 Receptor Antagonist For The Treatment Of Refractory Or Unexplained Chronic Cough In A Phase 2b Randomised Controlled Trial. The lancet. Respiratory medicine, https://doi.org/10.1016/S2213-2600%2819%2930471-0

Background: Gefapixant is a P2X3 receptor antagonist in development for treatment of refractory (RCC) and unexplained chronic cough (UCC). Methods: We conducted a 12-week, Phase 2b, randomized, double-blind, placebo-controlled study in patients w... Read More about Gefapixant A P2X3 Receptor Antagonist For The Treatment Of Refractory Or Unexplained Chronic Cough In A Phase 2b Randomised Controlled Trial.

ERS guidelines on the diagnosis and treatment of chronic cough in adults and children (2019)
Journal Article
Morice, A. H., Millqvist, E., Bieksiene, K., Birring, S. S., Dicpinigaitis, P., Ribas, C. D., …Zacharasiewicz, A. (in press). ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. The European respiratory journal, https://doi.org/10.1183/13993003.01136-2019

These guidelines incorporate the recent advances in chronic cough pathophysiology, diagnosis and treatment. The concept of cough hypersensitivity has allowed an umbrella term that explains the exquisite sensitivity of patients to external stimuli suc... Read More about ERS guidelines on the diagnosis and treatment of chronic cough in adults and children.

Textural analysis demonstrates heterogeneous [18F]-fluorodeoxyglucose uptake in radiologically normal lung in patients with idiopathic pulmonary fibrosis (2018)
Journal Article
Aliyu, S. A., Avery, G., Cawthorne, C., Archibald, S. J., Kadir, T., Willaime, J. M., …Crooks, M. G. (2018). Textural analysis demonstrates heterogeneous [18F]-fluorodeoxyglucose uptake in radiologically normal lung in patients with idiopathic pulmonary fibrosis. The European respiratory journal, 52(5), 1801138. https://doi.org/10.1183/13993003.01138-2018

Positron Emission Tomography (PET) scanning in idiopathic pulmonary fibrosis (IPF) has revealed increased [18F]-fluorodeoxyglucose ([18F]-FDG) uptake in areas of the lungs that appear normal on high resolution computed tomography (HRCT). We hypothesi... Read More about Textural analysis demonstrates heterogeneous [18F]-fluorodeoxyglucose uptake in radiologically normal lung in patients with idiopathic pulmonary fibrosis.

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial (2017)
Journal Article
Birring, S. S., Wijsenbeek, M. S., Agrawal, S., van den Berg, J. W., Stone, H., Maher, T. M., …Morice, A. (2017). A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. The lancet. Respiratory medicine, 5(10), 806-815. https://doi.org/10.1016/S2213-2600%2817%2930310-7

Background Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and is difficult to treat. PA101 is a novel formulation of sodium cromoglicate delivered via a high-efficiency eFlow nebuliser that achieves significantly higher dr... Read More about A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.

Theobromine for the treatment of persistent cough: A randomised, multicentre, double-blind, placebo-controlled clinical trial (2017)
Journal Article
Morice, A. H., McGarvey, L., Pavord, I. D., Higgins, B., Chung, K. F., & Birring, S. S. (2017). Theobromine for the treatment of persistent cough: A randomised, multicentre, double-blind, placebo-controlled clinical trial. Journal of thoracic disease, 9(7), 1864-1872. https://doi.org/10.21037/jtd.2017.06.18

© Journal of Thoracic Disease. Background: To investigate the effect of BC1036 on health-related quality of life (QOL) in subjects with persistent cough. The secondary objective was to investigate the effect of BC1036 on subjective cough severity. Me... Read More about Theobromine for the treatment of persistent cough: A randomised, multicentre, double-blind, placebo-controlled clinical trial.

Tussive challenge with ATP and AMP: does it reveal cough hypersensitivity? (2017)
Journal Article
Fowles, H. E., Rowland, T., Wright, C., & Morice, A. (2017). Tussive challenge with ATP and AMP: does it reveal cough hypersensitivity?. The European respiratory journal, 49(2), https://doi.org/10.1183/13993003.01452-2016

Recent studies have demonstrated that blockade of P2X3 adenosine triphosphate (ATP) receptors may profoundly inhibit chronic cough. We have considered whether inhaled ATP produces a tussive response and whether chronic cough patients are hypersensiti... Read More about Tussive challenge with ATP and AMP: does it reveal cough hypersensitivity?.

The online Cough Clinic: Developing guideline-based diagnosis and advice (2009)
Journal Article
Dettmar, P. W., Strugala, V., Fathi, H., Dettmar, H. J., Wright, C., & Morice, A. H. (2009). The online Cough Clinic: Developing guideline-based diagnosis and advice. The European respiratory journal, 34(4), 819-824. doi:10.1183/09031936.00126908

The aim of the present study was make chronic cough guidelines more practical and user friendly by developing an internet-based interactive diagnostic questionnaire for chronic cough. A prospective cohort study of chronic cough sufferers was conducte... Read More about The online Cough Clinic: Developing guideline-based diagnosis and advice.

Inflammatory mediators modulate thrombin and cathepsin-G signaling in human bronchial fibroblasts by inducing expression of proteinase-activated receptor-4 (2007)
Journal Article
Ramachandran, R., Sadofsky, L., Xiao, Y., Botham, A., Cowen, M., Morice, A., & Compton, S. J. (2007). Inflammatory mediators modulate thrombin and cathepsin-G signaling in human bronchial fibroblasts by inducing expression of proteinase-activated receptor-4. American journal of physiology. Lung cellular and molecular physiology, 292(3), L788-L798. doi:10.1152/ajplung.00226.2006

Human lung fibroblasts express proteinase-activated receptor-1 (PAR 1 ), PAR 2 and PAR 3 , but not PAR 4 . Because PAR 2 has inflammatory effects on human primary bronchial fibroblasts (HPBF), we asked 1) whether the inflammatory mediators TNF-α and... Read More about Inflammatory mediators modulate thrombin and cathepsin-G signaling in human bronchial fibroblasts by inducing expression of proteinase-activated receptor-4.


;